ExploreWatchlistsPricing
  1. US-listed companies
  2. Eloxx Pharmaceuticals, Inc.
  3. Financials
  4. Stock-based compensation

Eloxx Pharmaceuticals, Inc. (ELOX)

Market cap
$89.82M
P/E ratio
SummaryFinancials
Period EndStock-based compensation (Million USD)YoY (%)
Dec 31, 20250-92.22%
Dec 31, 20223-67.04%
Dec 31, 20219+5.78%
Dec 31, 20209-23.55%
Dec 31, 201911-15.21%
Dec 31, 201813+13137.62%
Dec 31, 20170+26.08%
Jun 30, 20170-48.87%
Jun 30, 20160-67.40%
Jun 30, 20150-62.95%
Jun 30, 20141-89.89%
Jun 30, 201313

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat